US · DYN
Dyne Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Waltham, MA 02451
- Website
- dyne-tx.com
Price · as of 2024-12-31
$17.39
Market cap 2.57B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $13.13 | $0.00 | |||
| 2011 | $0.00 | $300.51 | |||
| 2012 | $29.38 | $0.00 | |||
| 2013 | $4.30 | $0.00 | |||
| 2014 | $21.33 | $0.00 | |||
| 2015 | $18.99 | $0.00 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $9.31 | $0.00 | |||
| 2018 | |||||
| 2019 | |||||
| 2020 | $16.84 | ||||
| 2021 | $8.74 | ||||
| 2022 | $13.09 | ||||
| 2023 | $25.16 | ||||
| 2024 | $12.40 |
AI valuation
Our deep-learning model estimates Dyne Therapeutics, Inc.'s (DYN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $17.39
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DYN | Dyne Therapeutics, Inc. | $17.39 | 2.57B | — | — | — | — | -3.68 | 1.85 | — | -1.74 | — | 1.85 | 0.00% | — | — | -88.03% | -9599.05% | -74.14% | 0.04 | — | 15.60 | 15.20 | 1.31 | -1468.00% | — | 5604.00% | -25.25% | -6.92 | -8227.36% | 0.00% | 0.00% | 27.18% | -1.60 | -1.86 | — | 8.91 |
| AAPG | ASCENTAGE PHARMA GROUP IN… | $24.00 | 557.78M | -51% | -67% | — | — | -27.16 | 40.63 | 10.95 | -46.99 | — | 65.65 | 97.03% | -37.70% | -41.34% | -243.53% | -49.87% | -15.45% | 6.32 | -5.74 | 1.26 | 1.14 | -1.82 | -8979.00% | 34177.00% | -8267.00% | -1.26% | -0.10 | -18.30% | 0.00% | 0.00% | 2.74% | -30.20 | -82.32 | 11.39 | -0.29 |
| APGE | Apogee Therapeutics, Inc. | $70.00 | 3.84B | — | — | — | — | -10.95 | 2.78 | — | -6.86 | -11.08 | 2.78 | 0.00% | — | — | -33.22% | -223.05% | -31.53% | 0.02 | — | 18.55 | 18.39 | 0.60 | 9880.00% | — | 12999.00% | -8.64% | -5.99 | -177.24% | 0.00% | 0.00% | 0.69% | -6.85 | -8.62 | — | 31.49 |
| CELC | Celcuity Inc. | $111.71 | 5.17B | — | — | — | — | -3.76 | 3.63 | — | -2.79 | -72.15 | 3.63 | 0.00% | — | — | -87.54% | 909.82% | -51.23% | 0.85 | -11.02 | 7.71 | 7.46 | -0.74 | 520.00% | — | 5529.00% | -19.94% | -2.63 | 672.45% | 0.00% | 0.00% | 0.00% | -2.49 | -3.38 | — | -0.09 |
| CGON | CG Oncology, Inc. Common … | $58.80 | 4.74B | +6% | +153% | — | — | -27.73 | 5.93 | 1105.21 | -23.38 | -58.37 | 6.02 | -15.02% | -4722.13% | -3985.02% | -21.67% | -4199.76% | -20.82% | 0.01 | — | 24.63 | 24.09 | 0.16 | 4752.00% | 25470.00% | 6781.00% | -2.97% | -4.29 | -2916.46% | 0.00% | 0.00% | 0.00% | -19.55 | -28.15 | 923.25 | 68.35 |
| CNTA | Centessa Pharmaceuticals … | $26.86 | 3.61B | +34% | — | — | — | -7.88 | 4.63 | — | -6.73 | -25.25 | 4.63 | 0.00% | — | — | -73.93% | -398.61% | -50.32% | 0.29 | -19.93 | 9.25 | 9.09 | 1.20 | 3121.00% | -10000.00% | -1148.00% | -7.65% | -2.45 | -281.71% | 0.00% | 0.00% | 11.98% | -7.43 | -10.51 | — | 3.81 |
| MIRM | Mirum Pharmaceuticals, In… | $92.29 | 4.77B | -16% | +4,973% | -96% | — | -193.57 | 14.37 | 8.67 | 259.00 | — | 84.11 | 80.71% | -4.25% | -4.48% | -8.65% | -8.65% | -3.09% | 1.01 | -1.54 | 2.67 | 2.46 | 1.20 | -7459.00% | 5474.00% | 48801.00% | 1.21% | 0.27 | 21.44% | 0.00% | 0.00% | 1.65% | -201.32 | 81.21 | 8.55 | 5.05 |
| RARE | Ultragenyx Pharmaceutical… | $23.39 | 2.26B | -15% | -61% | — | — | -3.95 | -28.37 | 3.37 | -5.71 | — | -7.57 | 83.80% | -79.49% | -85.44% | -656.03% | -567.31% | -37.89% | -15.95 | -8.63 | 2.48 | 2.22 | -1.68 | -731.00% | 2013.00% | 1193.00% | -20.80% | -1.21 | -500.50% | 0.00% | 0.00% | 0.00% | -5.33 | -6.04 | 4.24 | -3.56 |
| SLNO | Soleno Therapeutics, Inc. | $39.07 | 2.1B | — | -51% | -73% | — | 99.43 | 4.61 | 10.91 | 62.51 | — | 4.66 | 98.58% | 7.85% | 10.97% | 6.01% | 19.44% | 4.67% | 0.01 | 2.73 | 5.80 | 5.44 | -2.38 | -10890.00% | — | -16741.00% | 2.25% | 0.76 | 60.75% | 0.00% | 0.00% | 6.38% | 118.68 | 37.97 | 9.32 | 10.94 |
| TLX | Telix Pharmaceuticals Lim… | $7.25 | 2.43B | +233% | +1,741% | -93% | — | -340.42 | 5.85 | 3.02 | 52.73 | — | -13.68 | 53.11% | 2.21% | -0.89% | -1.80% | 3.26% | -0.65% | 1.26 | 0.48 | 1.43 | 1.21 | 7.16 | -12257.00% | 5391.00% | -38842.00% | -2.28% | -0.07 | -10.14% | 0.00% | 0.00% | 0.00% | 158.00 | -50.84 | 3.49 | 2.55 |
| XENE | Xenon Pharmaceuticals Inc… | $43.23 | 3.34B | — | -58% | — | — | -9.75 | 5.80 | 449.63 | -8.27 | -21.74 | 5.80 | 66.09% | -4974.27% | -4612.13% | -51.76% | -419.58% | -48.34% | 0.01 | — | 13.13 | 13.17 | 0.56 | 4485.00% | — | 5175.00% | -8.30% | -6.68 | -314.81% | 0.00% | 0.00% | 1.71% | -7.59 | -10.11 | 377.51 | 35.64 |
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
- CEO
- John G. Cox
- Employees
- 192
- Beta
- 1.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $17.39) − 1 = — (DCF, example).